FIELD: medicine, phthisiology. SUBSTANCE: invention relates to chemotherapeutic antibacterial agents used for treatment of tuberculosis patients. Tuberculostat agent comprises a mixture of isonicotinic acid isoniazide-hydrazide in concentration 0.8 mcg/ml, not less, and 2,4-dioxo-5-fluoropyrimidine in concentration 300 mcg/ml and above. Invention ensures to suppress the growth of tuberculosis mycobacterium strains both sensitive and resistant to isoniazide that is very important in phthisiology. EFFECT: enhanced effectiveness of agent. 5 tbl
Title | Year | Author | Number |
---|---|---|---|
TUBERCULOSTATIC AGENT | 1998 |
|
RU2153339C1 |
METHOD FOR TREATING THE CASES OF EXPERIMENTAL TUBERCULOSIS | 2000 |
|
RU2165761C1 |
ANTI-TUBERCULOSIS PREPARATION | 2002 |
|
RU2211035C1 |
TUBERCULOSTATIC AGENT | 2002 |
|
RU2207126C1 |
METHOD FOR TREATING THE CASES OF TUBERCULOSIS | 2002 |
|
RU2212240C1 |
METHOD OF TREATMENT OF EXPERIMENTAL TUBERCULOSIS | 2001 |
|
RU2207127C1 |
METHOD OF TREATING PULMONARY TUBERCULOSIS FEATURING PREDOMINANTLY EXUDATIVE TYPE OF INFLAMMATION | 1990 |
|
RU2008902C1 |
AGENT ENHANCING EFFECTIVENESS OF TREATMENT OF PATIENTS WITH TUBERCULOSIS | 1996 |
|
RU2136276C1 |
DRUG PREPARATION FOR TREATING TUBERCULOSIS | 2013 |
|
RU2523792C9 |
METHOD FOR TREATING PULMONARY TUBERCULOSIS AT PREDOMINANTLY PRODUCTIVE TYPE OF TISSUE REACTION | 2000 |
|
RU2204409C2 |
Authors
Dates
2002-07-20—Published
2001-01-29—Filed